ELAN Insider Timothy J Bettington Sells $100K of Stock

Timothy J Bettington, an insider at Elanco Animal Health Incorporated NYSE: ELAN, sold 4,350 shares of the company on October 15, 2026. The transaction was revealed in a Form 4 filed with the Securities and Exchange Commission. The shares were sold at a price of $23.00 for a total value of $100,050.00.

ELAN Elanco Animal Health Incorporated

$23.55 ▲ +4.57% year to date

1M 3M YTD

Daily close · Oct 16, 2026

Inside Timothy J Bettington's Elanco Trade

The sale was carried out under a pre-arranged trading plan, often called a Rule 10b5-1 plan. Following the transaction, Bettington held 138,911 shares of the company. This move trimmed the insider's stake by about 3.04%. The stock closed at $23.54 on the day of the transaction.

Other Institutional Activity in Elanco

Large institutional funds have also adjusted their positions in the animal health firm recently. Dodge & Cox reduced its holdings by 10,140,205 shares, ending with 68,944,100 shares worth about $1,705,677,018.22. Dodge & Cox Inc. cut its stake by 1,544,285 shares to finish with 67,397,025 shares valued at approximately $1,583,156,101.00. Primecap Management Company trimmed its position by 394,217 shares, leaving it with 45,445,012 shares worth about $1,067,503,321.00. Winslow Capital Management, LLC lowered its holdings by 103,471 shares to end with 13,511,127 shares valued at roughly $317,376,370.00.

Elanco Animal Health Incorporated Stock Up 4.2%

Elanco shares recently traded around $23.49 as of October 19, 2026. That is down slightly from the event closing price of $23.54 on October 15. The stock trades above its 50-day moving average of $23.24 but sits below its 200-day moving average of $23.81.

Recent Earnings

Elanco reported trailing-twelve-month revenue of $5,020,000,256.00 alongside negative earnings per share of $0.41. The company posted a net profit margin of -4.0% and a return on equity of -3.0%. Revenue grew 10.2% year-over-year. The next earnings report is scheduled for November 6, 2026.

Insider Buying and Selling at Elanco Animal Health Incorporated

Other company insiders have completed transactions in recent months. Director Paul S Herendeen bought 10,000 shares on August 7, 2026, at an average price of $23.68. Director Michael J Harrington purchased 5,000 shares on August 12, 2026, at $21.82 per share. Officer Shiv O'Neill acquired 3,998 shares on August 18, 2026, at $23.58. Director Lawrence Erik Kurzius bought 40,000 shares on August 20, 2026, at $23.40 per share.

Analysts Set New Price Targets

Wall Street firms continue to update their views on the stock. Morgan Stanley maintained an Equal-Weight rating with a $26.00 price target on July 22, 2026. UBS kept a Buy rating and raised its target to $33.00 on August 6, 2026. Keybanc maintained an Overweight rating with a $30.00 target on the same day. Later, Goldman Sachs initiated coverage with a Buy rating and a $32.00 target on October 16, 2026. The stock carries a consensus rating of strong buy with a mean price target of $31.07 across 14 analyst opinions.

About Elanco

Elanco Animal Health Incorporated is an independent company based in Indianapolis, Indiana. The firm focuses on the discovery, development, and delivery of products to protect and improve the health of pets and farm animals around the globe. This trade arrives as the company prepares for its upcoming quarterly financial update in early November.

Bottom Line

Timothy J Bettington's planned sale provides a look at individual insider portfolio adjustments at Elanco. Investors will monitor the company's upcoming earnings release on November 6, 2026, for further insight into financial performance and revenue growth.